10-Q: Stepan Q2 Net Income Rises 19% on Strong Sales

Stepan Company reported a 19% increase in second-quarter net income to $11.3 million, with net sales growing 7% to $594.7 million, driven by higher selling prices and sales volume.

Summary

• Net income for the second quarter of 2025 increased 19% to $11.3 million, or $0.50 per diluted share, compared to $9.5 million, or $0.42 per diluted share, in the second quarter of 2024.
• Consolidated net sales for the second quarter of 2025 rose 7% to $594.7 million from $556.4 million in the prior year quarter, primarily due to higher average selling prices ($32.5 million) and increased sales volume ($7.5 million).
• For the first half of 2025, net income increased 32.6% to $31.1 million, or $1.36 per diluted share, up from $23.4 million, or $1.02 per diluted share, in the first half of 2024.
• Consolidated net sales for the first half of 2025 increased 7% to $1,187.9 million, compared to $1,107.8 million in the first half of 2024, driven by higher average selling prices ($72.9 million) and increased sales volume ($27.4 million).
• EBITDA for the second quarter of 2025 was $50.6 million, up 6%, and Adjusted EBITDA was $51.4 million, up 8% year-over-year.
• EBITDA for the first half of 2025 was $108.6 million, up 11%, and Adjusted EBITDA was $108.9 million, up 10% year-over-year.
• The effective tax rate significantly decreased to 17.7% in Q2 2025 from 44.7% in Q2 2024, and to 19.2% in H1 2025 from 36.1% in H1 2024, due to a favorable tax audit settlement and non-recurrence of a prior unfavorable GILTI-related event.
• Polymer segment operating income increased 26% in Q2 2025 and 15% in H1 2025, driven by higher sales volume and improved margins.
• Surfactant segment operating income decreased 22% in Q2 2025 and 2% in H1 2025, impacted by higher raw material costs, startup expenses for the new Pasadena, Texas facility, and an EPA penalty.
• Specialty Products operating income decreased 28% in Q2 2025 and 7% in H1 2025, primarily due to order timing differences in the pharmaceutical business.
• Cash from operating activities was a source of $18.1 million for the first six months of 2025, a significant decrease from $71.1 million in the comparable period of 2024, mainly due to higher working capital use.
• Total debt increased to $658.0 million at June 30, 2025, from $625.4 million at December 31, 2024, primarily due to the issuance of $75.0 million in senior unsecured notes.

Sentiment

Score: 7

Explanation: The company reported strong net income and sales growth, along with a significantly lower effective tax rate. However, a substantial decrease in cash from operating activities and ongoing environmental liabilities present areas of concern, leading to a moderately positive sentiment.

Positives

• Net income increased significantly by 19% in Q2 2025 and 32.6% in H1 2025, demonstrating strong profitability growth.
• Diluted earnings per share (EPS) rose to $0.50 in Q2 2025 and $1.36 in H1 2025, indicating improved shareholder value.
• Consolidated net sales grew 7% in both Q2 and H1 2025, driven by favorable selling prices and increased sales volume.
• EBITDA and Adjusted EBITDA showed healthy increases in both the three and six-month periods, reflecting improved operational performance.
• The effective tax rate decreased substantially due to a favorable tax audit settlement and the non-recurrence of a prior unfavorable tax event.
• The Polymer segment demonstrated strong performance with a 26% increase in operating income in Q2 2025, benefiting from increased sales volume and improved unit margins.
• Corporate expenses, excluding deferred compensation and restructuring, decreased by 18% in Q2 2025 and 10% in H1 2025, partly due to the non-recurrence of a $3.5 million charge related to a criminal social engineering scheme in the prior year.

Negatives

• Operating income for the second quarter of 2025 decreased 4% year-over-year, despite higher net sales.
• Surfactant segment operating income declined by 22% in Q2 2025 and 2% in H1 2025, impacted by higher raw material costs, startup expenses for the new Pasadena, Texas alkoxylation facility, and an environmental remediation reserve adjustment.
• Specialty Products operating income decreased by 28% in Q2 2025 and 7% in H1 2025, primarily due to order timing differences in the pharmaceutical business.
• Cash provided by operating activities significantly decreased to $18.1 million in H1 2025 from $71.1 million in H1 2024, largely due to higher working capital requirements.
• Working capital was a cash use of $74.7 million in H1 2025, a substantial increase from $15.5 million cash use in H1 2024, reflecting higher inventories and receivables.
• Net interest expense increased by $2.8 million in Q2 2025 and $3.9 million in H1 2025, primarily due to lower capitalized interest income as the new Pasadena facility started operations.
• Foreign currency translation had an unfavorable impact on net sales and operating income in both periods.
• The company incurred a $1.1 million USEPA penalty for FIFRA violations related to biocide products, which contributed to increased selling expenses.

Risks

• Accidents, unplanned production shutdowns, or disruptions in manufacturing facilities.
• Reduced demand for products due to customer product reformulations or new technologies.
• Inability to successfully develop or introduce new products.
• Compliance with environmental, health and safety, product registration, and anti-corruption laws.
• Inability to successfully acquire and integrate suitable candidates.
• Global competition and ability to successfully compete.
• Volatility of raw material, natural gas, and electricity costs, as well as supply disruptions.
• Disruptions in transportation or significant changes in transportation costs.
• Downturns in certain industries and general economic downturns.
• International business risks, including changes in global trade policy, tariffs, currency exchange controls, fluctuations in currency exchange rates, legal restrictions, and taxes.
• Unfavorable resolution of litigation against the company.
• Inability to keep and protect intellectual property rights.
• Potentially adverse tax consequences due to the international scope of operations.
• Downgrades to credit ratings or disruptions to access well-functioning capital markets.
• Conflicts, military actions, terrorist attacks, and general instability, particularly in energy-producing nations.
• Cost overruns, delays, and miscalculations in capacity needs with respect to expansion or other capital projects.
• Interruption of, damage to, or compromise of IT systems and failure to maintain data integrity.
• Inability to retain executive management and other key personnel.
• Inability to operate within the limitations of debt covenants.

Future Outlook

The company estimates total capital expenditures for 2025 to be in the range of $120.0 million to $125.0 million. Management believes the 2025 U.S. tax act, signed on July 4, 2025, will not have a material impact on the company's financial results, financial position, liquidity, or cash flows for 2025. The company anticipates that cash from operations, committed credit facilities, and cash on hand will be sufficient to fund anticipated capital expenditures, working capital, dividends, and other planned financial commitments for the foreseeable future.

Management Comments

• Management believes that the disclosures are adequate and make the information presented not misleading.
• Management believes that all adjustments, consisting only of normal recurring accruals, necessary to present fairly the company's financial position, results of operations, and cash flows have been included.
• Management believes that the company has made adequate provisions for the costs it is likely to incur with respect to legal and environmental claims.
• Management believes that the company has no material liability at certain environmental sites and that these matters, individually and in the aggregate, will not have a material effect on the company's financial position.
• Management's opinion is that the company's liquidity is sufficient to provide for potential increases in working capital requirements during 2025.
• The President and Chief Executive Officer, Luis E. Rojo, and the Vice President and Chief Financial Officer, Ruben Velasquez, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact, and that the financial statements fairly present the financial condition, results of operations, and cash flows.

Industry Context

The company operates in a mixed industry environment. The Polymer segment benefited from the market exit of a competitor, leading to double-digit growth in commodity phthalic anhydride sales volume. Demand for products in agricultural and oilfield end markets showed strength, while demand for products in the commodity laundry and cleaning end markets was lower. The company is also pursuing product diversification efforts in specialty polyols.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company received a pre-filing notice from USEPA on March 19, 2025, for alleged violations of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) related to certain biocide products. A civil penalty of $1.126 million was assessed and paid on July 2, 2025, with the company pursuing indemnification claims against two third parties.
• Ongoing environmental remediation at the Maywood, New Jersey site, with a consent decree entered on February 29, 2024, requiring certain actions and payment of past costs. The ultimate amount of liability could differ materially from the current recorded liability.
• Ongoing remediation at the DImperio Property Site in New Jersey, where the company is cooperating with other potentially responsible parties. The ultimate cost could differ materially from the current recorded liability.
• Ongoing remediation at the Wilmington, Massachusetts site, with a consent decree dated September 28, 2023, requiring remedial design and action. The company is contractually obligated to contribute up to 5% of environmental response costs incurred by the current owner, with no limitation on the ultimate amount.
• A possible joint claim by federal and state trustees for alleged natural resource damages related to the Wilmington site was notified on July 29, 2022, with a liability recorded in Q1 2024. The ultimate resolution could differ materially.
• A Notice and Finding of Violation from the USEPA was received on March 26, 2024, alleging air regulation violations at the Elwood, Illinois (Millsdale) facility. The ultimate outcome and financial impact are currently unpredictable.
• Accrued an additional $1.754 million for remediation expenses at the Elwood, Illinois (Millsdale) facility in Q2 2025 due to a change in the scope of planned remediation activities.
• Self-remediation is required at Millsdale and Fieldsboro, New Jersey plants due to discovered chemical contamination levels above legal thresholds.
• A Brazil National Treasury rescission action was filed on June 12, 2023, against the company's Brazilian subsidiary to rescind its use of PIS/COFINS tax credits for the period from March 23, 2012, to March 15, 2017. The ultimate resolution could differ materially from the current recorded liability.

Stakeholder Impact

• Shareholders: Benefited from increased net income and diluted EPS, but cash dividends paid decreased slightly in H1 2025 compared to H1 2024. The share repurchase program has $125.1 million remaining, but no open market purchases were made in H1 2025.
• Employees: Stock-based compensation and profit sharing contributions were made, and the company's defined benefit pension plans are frozen, with no service benefits accruing.
• Customers: Experienced higher average selling prices due to the pass-through of raw material costs, but also benefited from product diversification efforts and a competitor's market exit in certain segments.
• Creditors: The company issued $75.0 million in senior unsecured notes, increasing total debt. The company remains in compliance with debt covenants, which limit additional debt, investments, and dividend payments.
• Regulatory Authorities: The company is subject to ongoing environmental regulations and legal proceedings, including an EPA penalty and various remediation efforts, indicating continued regulatory scrutiny and associated costs.

Next Steps

• Complete the sale of Stepan Philippines Quaternaries, Inc.'s manufacturing assets during the second half of 2025.
• Continue to evaluate the impact of the 2025 U.S. tax act on financial results, position, liquidity, and cash flows.
• Pursue indemnification claims against two third parties to recover the $1.1 million USEPA penalty paid on July 2, 2025.
• Manage ongoing environmental remediation activities at sites like Maywood, DImperio, Wilmington, and Millsdale.

Key Dates

Recommendation

While Stepan Company demonstrated strong net income and sales growth, coupled with a favorable tax rate, several factors warrant a 'hold' recommendation. The significant decline in cash from operating activities, driven by increased working capital use, raises concerns about liquidity and operational efficiency. The Surfactant and Specialty Products segments faced headwinds, offsetting the strong performance in Polymers. Additionally, ongoing environmental liabilities and a recent EPA penalty introduce financial uncertainties. The increase in debt, while managed within covenants, adds to the leverage. A seasoned investor would likely monitor the company's ability to improve cash flow from operations, manage its environmental exposures, and sustain growth across all segments before considering a stronger position.

Keywords

Chemicals, Surfactants, Polymers, Specialty Products, Insulation, Cleaning products, Agricultural chemicals, Pharmaceuticals, Industrial chemicals, Financial results, SEC filing, 10-Q